Dulaglutide: Uses, Mechanism, and Side Effects

Managing type 2 diabetes often means balancing blood sugar control with cardiovascular risk, and many patients want to know how their medication addresses both. Dulaglutide is a weekly injectable therapy built around a well-studied hormone pathway that does exactly that.

Key takeaways

• Dulaglutide is a GLP-1 receptor agonist sold under the brand name TRULICITY.
• It is approved to improve glycemic control in type 2 diabetes and to reduce major cardiovascular events in adults with the disease.
• The label carries a boxed warning.
• More than 148 trials have been registered involving this compound, including the large REWIND cardiovascular outcomes trial.
• FAERS reports are led by nausea, injection site pain, and elevated blood glucose readings.

What Dulaglutide Is

Dulaglutide belongs to the GLP-1 receptor agonist class and shares 90% amino acid sequence homology with the body's own GLP-1 hormone. It works by activating the GLP-1 receptor on pancreatic beta cells, which raises intracellular cyclic AMP and triggers insulin release only when blood glucose is elevated. The drug also lowers glucagon secretion and slows gastric emptying, actions that together help stabilize blood sugar levels.

What Dulaglutide Is Approved For

Dulaglutide, marketed as TRULICITY, is approved as an add-on to diet and exercise to improve glycemic control in adults and in pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is also approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The label for this product carries a boxed warning.

What the Evidence Shows

Dulaglutide has been studied across more than 148 registered clinical trials. Among them, the REWIND trial (NCT01394952), a completed Phase 3 study, examined cardiovascular events in patients using a weekly incretin therapy for diabetes. A separate completed Phase 3 study (NCT04809220) evaluated two dulaglutide doses in Japanese patients with type 2 diabetes.

Reported Side Effects

FAERS data reflect reported adverse events, not confirmed incidence or proven causation. The most frequently reported reactions involve the digestive system, led by nausea (10,405 reports), diarrhoea (6,090), and vomiting (5,787). Injection-related and glucose-monitoring issues are also common, including injection site pain (9,956 reports) and increased blood glucose readings (9,904). Administration errors, such as incorrect dose given or an inappropriate dosing schedule, along with reports of the drug being ineffective, appear as well.